Risk factors for treatment failure in osteoporotic patients with rheumatoid arthritis

References

• Deodhar AA, Woolf AD. Bone mass measurement and bone metabolism in rheumatoid arthritis: a review. Br J Rheumatol. 1996;35(4):309–22.
   PubMedGoogle Scholar
• Kanis JA. Diagnosis of osteoporosis and assessment of fracture risk. Lancet. 2002;359(9321):1929–36.
   PubMed Web of Science ®Google Scholar
• Cauley JA, Thompson DE, Ensrud KC, Scott JC, Black D. Risk of mortality following clinical fractures. Osteoporos Int. 2000;11(7):556–61.
   PubMed Web of Science ®Google Scholar
• Jakob F, Marin F, Martin-Mola E, Torgerson D, Fardellone P, Adami S, et al. Characterization of patients with an inadequate clinical outcome from osteoporosis therapy: the Observational Study of Severe Osteoporosis (OSSO). QJM. 2006;99(8):531–43.
   PubMed Web of Science ®Google Scholar
• Delmas PD. Treatment of postmenopausal osteoporosis. Lancet. 2002;359(9322):2018–26.
   PubMed Web of Science ®Google Scholar
• Diez-Perez A, Adachi JD, Adami S, Anderson FA, Jr., Boonen S, Chapurlat R, et al. Risk factors for treatment failure with antiosteoporosis medication: the global longitudinal study of osteoporosis in women (GLOW). J Bone Miner Res. 2014;29(1):260–7.
   PubMed Web of Science ®Google Scholar
• Body JJ, Bergmann P, Boonen S, Boutsen Y, Devogelaer JP, Goemaere S, et al. Evidence-based guidelines for the pharmacological treatment of postmenopausal osteoporosis: a consensus document by the Belgian Bone Club. Osteoporos Int. 2010;21(10):1657–80.
   PubMed Web of Science ®Google Scholar
• MacLean C, Newberry S, Maglione M, McMahon M, Ranganath V, Suttorp M, et al. Systematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis. Ann Intern Med. 2008;148(3):197–213.
   PubMed Web of Science ®Google Scholar
• Cortet B, Flipo RM, Blanckaert F, Duquesnoy B, Marchandise X, Delcambre B. Evaluation of bone mineral density in patients with rheumatoid arthritis. Influence of disease activity and glucocorticoid therapy. Rev Rhum Engl Ed. 1997;64(7–9):451–8.
   PubMedGoogle Scholar
• Cortet B, Guyot MH, Solau E, Pigny P, Dumoulin F, Flipo RM, et al. Factors influencing bone loss in rheumatoid arthritis: a longitudinal study. Clin Exp Rheumatol. 2000;18(6):683–90.
   PubMed Web of Science ®Google Scholar
• Lewiecki EM. Nonresponders to osteoporosis therapy. J Clin Densitom. 2003;6(4):307–14.
   PubMed Web of Science ®Google Scholar
• Diez-Perez A, Adachi JD, Agnusdei D, Bilezikian JP, Compston JE, Cummings SR, et al. Treatment failure in osteoporosis. Osteoporos Int. 2012;23(12):2769–74.
   PubMed Web of Science ®Google Scholar
• Ferrar L, Jiang G, Adams J, Eastell R. Identification of vertebral fractures: an update. Osteoporos Int. 2005;16(7):717–28.
   PubMed Web of Science ®Google Scholar
• van der Heijde DM, van 't Hof MA, van Riel PL, Theunisse LA, Lubberts EW, van Leeuwen MA, et al. Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score. Ann Rheum Dis. 1990;49(11):916–20.
   PubMed Web of Science ®Google Scholar
• Curtis JR, Westfall AO, Cheng H, Lyles K, Saag KG, Delzell E. Benefit of adherence with bisphosphonates depends on age and fracture type: results from an analysis of 101,038 new bisphosphonate users. J Bone Miner Res. 2008;23(9):1435–41.
   PubMed Web of Science ®Google Scholar
• Penning-van Beest FJ, Erkens JA, Olson M, Herings RM. Loss of treatment benefit due to low compliance with bisphosphonate therapy. Osteoporos Int. 2008;19(4):511–7.
   PubMed Web of Science ®Google Scholar
• Richards JS, Cannon GW, Hayden CL, Amdur RL, Lazaro D, Mikuls TR, et al. Adherence with bisphosphonate therapy in US veterans with rheumatoid arthritis. Arthritis Care Res (Hoboken). 2012;64(12):1864–70.
   PubMed Web of Science ®Google Scholar
• Carr AJ, Thompson PW, Cooper C. Factors associated with adherence and persistence to bisphosphonate therapy in osteoporosis: a cross-sectional survey. Osteoporos Int. 2006;17(11):1638–44.
   PubMed Web of Science ®Google Scholar
• Rabenda V, Hiligsmann M, Reginster JY. Poor adherence to oral bisphosphonate treatment and its consequences: a review of the evidence. Expert Opin Pharmacother. 2009;10(14):2303–15.
   PubMed Web of Science ®Google Scholar
• McCombs JS, Thiebaud P, McLaughlin-Miley C, Shi J. Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas. 2004;48(3):271–87.
   PubMed Web of Science ®Google Scholar
• Adami S, Isaia G, Luisetto G, Minisola S, Sinigaglia L, Gentilella R, et al. Fracture incidence and characterization in patients on osteoporosis treatment: the ICARO study. J Bone Miner Res. 2006;21(10):1565–70.
   PubMed Web of Science ®Google Scholar
• Sakuma M, Endo N. [Space flight/bedrest immobilization and Bone. Exercise training for osteoporosis]. Clin Calcium. 2012;22(12): 1903–7.
   PubMedGoogle Scholar
• Kinoshita Y, Fukumoto S. [Space flight/bedrest immobilization and bone. Medical treatment for immobilization osteoporosis]. Clin Calcium. 2012;22(12):1895–901.
   PubMedGoogle Scholar
• Vis M, Guler-Yuksel M, Lems WF. Can bone loss in rheumatoid arthritis be prevented? Osteoporos Int. 2013;24(10):2541–53.
   PubMed Web of Science ®Google Scholar
• Francis RM. Non-response to osteoporosis treatment. J Br Menopause Soc. 2004;10(2):76–80.
   PubMedGoogle Scholar
• Wijbrandts CA, Klaasen R, Dijkgraaf MG, Gerlag DM, van Eck-Smit BL, Tak PP. Bone mineral density in rheumatoid arthritis patients 1 year after adalimumab therapy: arrest of bone loss. Ann Rheum Dis. 2009;68(3):373–6.
   PubMed Web of Science ®Google Scholar
• van der Goes MC, Jacobs JW, Jurgens MS, Bakker MF, van der Veen MJ, van der Werf JH, et al. Are changes in bone mineral density different between groups of early rheumatoid arthritis patients treated according to a tight control strategy with or without prednisone if osteoporosis prophylaxis is applied? Osteoporos Int. 2013;24(4):1429–36.
   PubMed Web of Science ®Google Scholar
• Matuszewska A, Szechinski J. Evaluation of Selected Bone Metabolism Markers in Rheumatoid Arthritis Patients. Adv Clin Exp Med. 2013;22(2):193–202.
   PubMed Web of Science ®Google Scholar
• Book C, Karlsson M, Akesson K, Jacobsson L. Disease activity and disability but probably not glucocorticoid treatment predicts loss in bone mineral density in women with early rheumatoid arthritis. Scand J Rheumatol. 2008;37(4):248–54.
   PubMed Web of Science ®Google Scholar
• Sugioka Y, Koike T. [Fall risk and fracture. Associated factors for falls in patients with inflammatory polyarthritis]. Clin Calcium. 2013;23(5):701–5.
   PubMedGoogle Scholar
• Mohammad A, Lohan D, Bergin D, Mooney S, Newell J, O’Donnell M, et al. The prevalence of vertebral fracture on vertebral fracture assessment imaging in a large cohort of patients with rheumatoid arthritis. Rheumatology (Oxford). 2014;53(5):821–7.
   PubMed Web of Science ®Google Scholar
• Krieckaert CL, Nurmohamed MT, Wolbink G, Lems WF. Changes in bone mineral density during long-term treatment with adalimumab in patients with rheumatoid arthritis: a cohort study. Rheumatology (Oxford). 2013;52(3):547–53.
   PubMed Web of Science ®Google Scholar
• Baschant U, Lane NE, Tuckermann J. The multiple facets of glucocorticoid action in rheumatoid arthritis. Nat Rev Rheumatol. 2012;8(11):645–55.
   PubMed Web of Science ®Google Scholar
• van Staa TP, Leufkens HG, Cooper C. The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int. 2002;13(10):777–87.
   PubMed Web of Science ®Google Scholar
• Villa P, Moruzzi MC, Lassandro AP, Leoni F, Di Nardo F, De Waure C, et al. Glucocorticoid therapy as a significant risk factor for osteoporosis and fractures in an Italian postmenopausal population. Gynecol Endocrinol. 2013;29(7):678–82.
   PubMed Web of Science ®Google Scholar
• Canalis E, Mazziotti G, Giustina A, Bilezikian JP. Glucocorticoid-induced osteoporosis: pathophysiology and therapy. Osteoporos Int. 2007;18(10):1319–28.
   PubMed Web of Science ®Google Scholar
• van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C. Oral corticosteroids and fracture risk: relationship to daily and cumulative doses. Rheumatology (Oxford). 2000;39(12):1383–9.
   PubMed Web of Science ®Google Scholar
• Grossman JM, Gordon R, Ranganath VK, Deal C, Caplan L, Chen W, et al. American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res (Hoboken). 2010;62(11):1515–26.
   PubMed Web of Science ®Google Scholar
• Mobini M, Kashi Z, Ghobadifar A. Prevalence and associated factors of osteoporosis in female patients with rheumatoid arthritis. Caspian J Intern Med. 2012;3(3):447–50.
   PubMedGoogle Scholar
• Furuya T, Inoue E, Hosoi T, Taniguchi A, Momohara S, Yamanaka H. Risk factors associated with the occurrence of hip fracture in Japanese patients with rheumatoid arthritis: a prospective observational cohort study. Osteoporos Int. 2013;24(4):1257–65.
   PubMed Web of Science ®Google Scholar
• Haugeberg G, Uhlig T, Falch JA, Halse JI, Kvien TK. Bone mineral density and frequency of osteoporosis in female patients with rheumatoid arthritis: results from 394 patients in the Oslo County Rheumatoid Arthritis register. Arthritis Rheum. 2000;43(3):522–30.
   PubMed Web of Science ®Google Scholar
• Dao HH, Do QT, Sakamoto J. Bone mineral density and frequency of osteoporosis among Vietnamese women with early rheumatoid arthritis. Clin Rheumatol. 2011;30(10):1353–61.
   PubMed Web of Science ®Google Scholar
• Marotte H, Pallot-Prades B, Grange L, Gaudin P, Alexandre C, Miossec P. A 1-year case-control study in patients with rheumatoid arthritis indicates prevention of loss of bone mineral density in both responders and nonresponders to infliximab. Arthritis Res Ther. 2007;9(3):R61.
   PubMed Web of Science ®Google Scholar